M., Rao M., Steffes A., Bostom J.H., Ix Supplementary Material for: Effect of Niacin on FGF23 Concentration in Chronic Kidney Disease <b><i>Background:</i></b> Elevated serum phosphorus and FGF23 are independent cardiovascular risk factors in patients with chronic kidney disease. In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D<sub>2</sub> receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations. <b><i>Methods:</i></b> This is an ancillary study to a multicenter, randomized, double-blind, placebo-controlled trial among patients with dyslipidemia and an estimated glomerular filtration rate (eGFR) of 30-74 ml/min/1.73 m<sup>2</sup>. Participants were randomized to ERN-L (n = 162), ERN (n = 97), or placebo (n = 68) in a 3:2:1 ratio for 24 weeks. The primary outcome was a change in serum FGF23 concentrations, and secondary outcomes were changes in other mineral metabolism parameters. <b><i>Results:</i></b> Both the ERN and ERN-L groups showed significant declines in serum phosphorus, calcium and calcium·phosphorus product at 24 weeks compared to placebo. A significant decline from baseline (10.9%, p < 0.01) in the serum FGF23 concentration was observed in the ERN group compared to placebo, but not in the ERN-L group compared to placebo (p = 0.36 and 0.97 for ERN-L and placebo, respectively), despite equivalent declines in serum phosphorus. Similarly, the most marked declines in PTH occurred in the ERN-only group versus placebo; no change in PTH was observed in the ERN-L group. <b><i>Conclusions:</i></b> In this ancillary study of hyperlipidemic patients with an eGFR of 30-74 ml/min/1.73 m<sup>2</sup>, ERN alone but not in combination with laropiprant lowered FGF23 and PTH concentrations. If confirmed, niacin may provide a novel strategy to decrease phosphorus, FGF23, and PTH concentrations in patients with chronic kidney disease. Niacin;Calcium;Phosphorus;Growth factor;Kidney disease;Cardiovascular disease 2014-05-20
    https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Effect_of_Niacin_on_FGF23_Concentration_in_Chronic_Kidney_Disease/5126458
10.6084/m9.figshare.5126458.v1